Trials / Unknown
UnknownNCT01693679
Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Shao-quan Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
• To estimate renoprotective efficacy of Telbivudine treated patients with HBV-related liver cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telbivudine, Lamivudine, Adefovir ,Enecavir | investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral. |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2014-04-01
- First posted
- 2012-09-26
- Last updated
- 2012-09-26
Source: ClinicalTrials.gov record NCT01693679. Inclusion in this directory is not an endorsement.